INACTIVE INGREDIENT SECTION
Inactive ingredients Ammonium Stearate, Calcium Carbonate, Glyceryl Abietate, Isopropyl Myristate, Natural
Rubber,Polybutene, Polyisobutylene, Propylene Carbonate, Styrene Copolymer, YS Resin, Zinc Oxide
Inactive ingredients Ammonium Stearate, Calcium Carbonate, Glyceryl Abietate, Isopropyl Myristate, Natural
Rubber,Polybutene, Polyisobutylene, Propylene Carbonate, Styrene Copolymer, YS Resin, Zinc Oxide
Active ingredients
DL-Camphor 1.2%
L-Menthol 2,.%
Methyl Salicylate 2.5%
Purpose
Topical Analgesic
Keep out of reach of children. If swallowed, get medical help or contact a poison control center immediately
Do not use
other than as directed on wounds, damaged or irritated skin in combination with other
external analgesic products, ointments, creams or with a heating pad. in contact with eyes or mucous
membranes. if you are allergic to any ingredient in this product or if you have a history of allergic reactions to this
or similar products
Stop Use and ask a
doctor if
rash, itching or excessive skin irritation develops
condition worsens
symptoms persist for more
than 7 days
if symptoms
subside and then reappear within a few days.
Warnings
For External Use Only
Directions
Adults and children 12 years of age and over: Clean and dry the affected area. Remove
patch from film backing. Adhere to area for no more than 8 hours at a time, not more than 3 times per day, and for no more
than 7 days continuously. Children under 12 years of age: Consult a doctor before use.
Uses
For temporary relief of minor aches and pains associated with:
Arthritis
Backaches
Sprains
Strains
Bruises
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1364097 | camphor 1.2 % / menthol 2.7 % / methyl salicylate 2.5 % Medicated Patch | PSN | 7 |
| 1364097 | camphor 0.012 MG/MG / menthol 0.027 MG/MG / methyl salicylate 0.025 MG/MG Medicated Patch | SCD | 7 |
| 1364097 | camphor 1.2 % / menthol 2.7 % / methyl salicylate 2.5 % Medicated Patch | SY | 7 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 53043-003-01 | 2019-11-27 | C162847 | 48780-1 | 9855d018-e3f3-cd31-e053-dbdaa90ab51a | Drug Facts |
| 53043-003-02 | 2019-11-27 | C162847 | 48780-1 | 9855d018-e3f3-cd31-e053-dbdaa90ab51a | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 53043-003-01 | Mini Pain Relief | 20 in 1 CARTON | PATCH | 20 | 7 | |
| 53043-003-02 | Mini Pain Relief | 20 in 1 CARTON | PATCH | 20 | 7 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CAMPHOR (SYNTHETIC) | ACTIVE INGREDIENT | 5TJD82A1ET | 7 | |
| LEVOMENTHOL | ACTIVE INGREDIENT | BZ1R15MTK7 | 7 | |
| METHYL SALICYLATE | ACTIVE INGREDIENT | LAV5U5022Y | 7 | |
| CAMPHOR (SYNTHETIC) | ACTIVE MOIETY | 5TJD82A1ET | 7 | |
| LEVOMENTHOL | ACTIVE MOIETY | BZ1R15MTK7 | 7 | |
| SALICYLIC ACID | ACTIVE MOIETY | O414PZ4LPZ | 7 | |
| AMMONIUM STEARATE | INACTIVE INGREDIENT | 37899330TZ | 7 | |
| CALCIUM CARBONATE | INACTIVE INGREDIENT | H0G9379FGK | 7 | |
| GLYCERYL ABIETATE | INACTIVE INGREDIENT | 2F22LY70Q1 | 7 | |
| ISOPROPYL MYRISTATE | INACTIVE INGREDIENT | 0RE8K4LNJS | 7 | |
| NATURAL LATEX RUBBER | INACTIVE INGREDIENT | 2LQ0UUW8IN | 7 | |
| POLYBUTENE (1400 MW) | INACTIVE INGREDIENT | 1NA5AO9GH7 | 7 | |
| POLYISOBUTYLENE (1000 MW) | INACTIVE INGREDIENT | 5XB3A63Y52 | 7 | |
| PROPYLENE CARBONATE | INACTIVE INGREDIENT | 8D08K3S51E | 7 | |
| STYRENE | INACTIVE INGREDIENT | 44LJ2U959V | 7 | |
| ZINC OXIDE | INACTIVE INGREDIENT | SOI2LOH54Z | 7 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 53043-003 | 53043-003-01, 53043-003-02 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CAMPHOR (SYNTHETIC) | 5TJD82A1ET | ACTIB |
| LEVOMENTHOL | BZ1R15MTK7 | ACTIB |
| METHYL SALICYLATE | LAV5U5022Y | ACTIB |
| AMMONIUM STEARATE | 37899330TZ | IACT |
| CALCIUM CARBONATE | H0G9379FGK | IACT |
| GLYCERYL ABIETATE | 2F22LY70Q1 | IACT |
| ISOPROPYL MYRISTATE | 0RE8K4LNJS | IACT |
| NATURAL LATEX RUBBER | 2LQ0UUW8IN | IACT |
| POLYBUTENE (1400 MW) | 1NA5AO9GH7 | IACT |
| POLYISOBUTYLENE (1000 MW) | 5XB3A63Y52 | IACT |
| PROPYLENE CARBONATE | 8D08K3S51E | IACT |
| STYRENE | 44LJ2U959V | IACT |
| ZINC OXIDE | SOI2LOH54Z | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OINTMENT / TOPICAL | 35 %w/w | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, EXTENDED RELEASE / ORAL | 229.7 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | CAPSULE, EXTENDED RELEASE / ORAL | 4 mg | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | SOLUTION / RESPIRATORY (INHALATION) | 3.11 %w/v | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | FILM, SOLUBLE / ORAL | 14 mg | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | INJECTION / SUBCUTANEOUS | 0.02 %w/v | ||
| PROPYLENE CARBONATE | PROPYLENE CARBONATE | 8D08K3S51E | OINTMENT / TOPICAL | 3000 mg | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | SOLUTION / INTRAVENOUS | 3.11 %w/v | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | SOLUTION / RESPIRATORY (INHALATION) | 4.02 %w/v | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | FILM, EXTENDED RELEASE / TRANSDERMAL | 20.4 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL, FOAM / TOPICAL | 144 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, COATED / ORAL | 64.8 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | GEL, METERED / TRANSDERMAL | 50 mg | ||
| POLYBUTENE (1400 MW) | POLYBUTENE (1400 MW) | 1NA5AO9GH7 | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | CREAM / TOPICAL | 65000 mg | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | INJECTION, SUSPENSION / SUBCUTANEOUS | NA | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SUSPENSION / AURICULAR (OTIC) | 0.02 %w/w | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | SUPPOSITORY / RECTAL | 375 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | GEL / TOPICAL | 29 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | SOLUTION / AURICULAR (OTIC) | 0.38 %w/w | ||
| POLYBUTENE (1400 MW) | POLYBUTENE (1400 MW) | 1NA5AO9GH7 | SYSTEM / TRANSDERMAL | 17.87 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | CAPSULE / ORAL | 349.9 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | GEL / TRANSDERMAL | 85 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | CAPSULE, DELAYED RELEASE / ORAL | 20 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SYSTEM / TRANSDERMAL | 113 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SYSTEM / TOPICAL | 7 mg | ||
| ZINC OXIDE | ZINC OXIDE | SOI2LOH54Z | LOTION / TOPICAL | 16 %w/w | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | FILM / TRANSDERMAL | 58.08 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, DELAYED RELEASE / ORAL | 8.4 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | LOTION / TOPICAL | 50 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | POWDER, DENTIFRICE / DENTAL | 0.5 mg/mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | SPRAY / TOPICAL | 3665 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | GUM, CHEWING / BUCCAL | 3492 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OIL / TOPICAL | 213 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, FILM COATED / ORAL | 300 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET / ORAL | 793 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL / TOPICAL | 9.3 %w/w | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | CREAM / VAGINAL | 50 mg | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | AEROSOL, SPRAY / TOPICAL | 6.89 %w/w | ||
| ISOPROPYL MYRISTATE | ISOPROPYL MYRISTATE | 0RE8K4LNJS | OIL / AURICULAR (OTIC) | 36 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, CHEWABLE / ORAL | 1650 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | SOLUTION / INTRAVENOUS | 4.02 %w/v |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 8dccfbae-5bf0-4c02-8c03-da491358efa7 | e1aae2c4-172f-4c73-9326-227828089360 | 2012-12-26 | Warnings | 8dccfbae-5bf0-4c02-8c03-da491358efa7 e1aae2c4-172f-4c73-9326-227828089360 |
Adverse event summaries are temporarily unavailable. Other product information remains available.